Medicines Development

Medicines Development for Global Health (MDGH) is a non-profit biopharmaceutical company dedicated to developing and delivering affordable medicines for neglected diseases. The company achieved a historic milestone in 2018 when it received FDA approval for moxidectin to treat onchocerciasis (river blindness), making it the first non-profit to ever receive a solo FDA approval for a new molecular entity. MDGH operates as a social enterprise, reinvesting any revenue into further research and development for diseases of poverty. Their pipeline focuses on expanding the use of moxidectin for other parasitic infections and developing new treatments for global health priorities.